NASDAQ:FTSV - Forty Seven News Headlines

$8.50
-0.25 (-2.86 %)
(As of 07/19/2019 04:00 PM ET)
Today's Range
$8.48
Now: $8.50
$8.80
50-Day Range
$8.63
MA: $10.59
$11.53
52-Week Range
$8.27
Now: $8.50
$23.83
Volume457,742 shs
Average Volume346,333 shs
Market Capitalization$266.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Forty Seven (NASDAQ FTSV) News Headlines

Source:
DateHeadline
Forty Seven prices stock offering at $8; shares down 6% after hoursForty Seven prices stock offering at $8; shares down 6% after hours
seekingalpha.com - July 18 at 12:13 PM
Forty Seven, Inc. Prices Underwritten Public Offering of 9,375,000 Shares of Common StockForty Seven, Inc. Prices Underwritten Public Offering of 9,375,000 Shares of Common Stock
finance.yahoo.com - July 18 at 12:13 PM
Forty Seven down 1% after hours on $75M stock offeringForty Seven down 1% after hours on $75M stock offering
seekingalpha.com - July 17 at 11:54 AM
Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common StockForty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock
finance.yahoo.com - July 17 at 11:54 AM
HC Wainwright Analysts Give Forty Seven (NASDAQ:FTSV) a $21.00 Price TargetHC Wainwright Analysts Give Forty Seven (NASDAQ:FTSV) a $21.00 Price Target
www.americanbankingnews.com - July 14 at 10:03 PM
Forty Seven, Inc. and Ono Pharmaceutical Co., Ltd. Sign Regional License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Select Countries in Southeast AsiaForty Seven, Inc. and Ono Pharmaceutical Co., Ltd. Sign Regional License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Select Countries in Southeast Asia
finance.yahoo.com - July 11 at 10:58 AM
Have Insiders Been Buying Forty Seven, Inc. (NASDAQ:FTSV) Shares?Have Insiders Been Buying Forty Seven, Inc. (NASDAQ:FTSV) Shares?
finance.yahoo.com - July 11 at 10:58 AM
Forty Seven Inc (NASDAQ:FTSV) Receives Average Rating of "Buy" from AnalystsForty Seven Inc (NASDAQ:FTSV) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - July 9 at 6:30 PM
Short Interest in Forty Seven Inc (NASDAQ:FTSV) Drops By 6.1%Short Interest in Forty Seven Inc (NASDAQ:FTSV) Drops By 6.1%
www.americanbankingnews.com - June 29 at 2:07 PM
-$0.69 EPS Expected for Forty Seven Inc (NASDAQ:FTSV) This Quarter-$0.69 EPS Expected for Forty Seven Inc (NASDAQ:FTSV) This Quarter
www.americanbankingnews.com - June 28 at 6:27 AM
Mark Anthony Mccamish Sells 8,199 Shares of Forty Seven Inc (NASDAQ:FTSV) StockMark Anthony Mccamish Sells 8,199 Shares of Forty Seven Inc (NASDAQ:FTSV) Stock
www.americanbankingnews.com - June 27 at 8:10 PM
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s LymphomaForty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
finance.yahoo.com - June 15 at 3:42 PM
Forty Seven (FTSV) Presents At 2019 ASCO Annual Meeting - SlideshowForty Seven (FTSV) Presents At 2019 ASCO Annual Meeting - Slideshow
seekingalpha.com - June 4 at 3:56 PM
Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid LeukemiaForty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
finance.yahoo.com - June 3 at 11:30 AM
Oppenheimer defends Forty Seven after 5F9-stoked plungeOppenheimer defends Forty Seven after 5F9-stoked plunge
seekingalpha.com - May 17 at 11:35 AM
Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology AssociationForty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association
finance.yahoo.com - May 16 at 9:19 AM
Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual MeetingForty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting
finance.yahoo.com - May 15 at 8:56 PM
Forty Seven, Inc. (FTSV)Forty Seven, Inc. (FTSV)
uk.finance.yahoo.com - May 14 at 4:08 PM
Forty Seven misses by $0.08Forty Seven misses by $0.08
seekingalpha.com - May 14 at 11:40 AM
Forty Seven Inc. Reports First Quarter 2019 Financial Results and Recent Business HighlightsForty Seven Inc. Reports First Quarter 2019 Financial Results and Recent Business Highlights
www.marketwatch.com - May 14 at 11:40 AM
Forty Seven Inc. (FTSV) Q1 2019 Earnings Call TranscriptForty Seven Inc. (FTSV) Q1 2019 Earnings Call Transcript
www.fool.com - May 14 at 2:10 AM
Forty Seven, Inc. to Host Earnings CallForty Seven, Inc. to Host Earnings Call
finance.yahoo.com - May 13 at 3:56 PM
Were Hedge Funds Right About Dumping Forty Seven, Inc. (FTSV)?Were Hedge Funds Right About Dumping Forty Seven, Inc. (FTSV)?
finance.yahoo.com - May 10 at 12:00 PM
Forty Seven Inc. to Report First Quarter 2019 Financial Results on Monday, May 13, 2019Forty Seven Inc. to Report First Quarter 2019 Financial Results on Monday, May 13, 2019
feeds.benzinga.com - May 6 at 4:28 PM
Forty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkins LymphomaForty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkin's Lymphoma
www.marketwatch.com - April 26 at 11:43 AM
Forty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkin’s LymphomaForty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkin’s Lymphoma
finance.yahoo.com - April 26 at 11:43 AM
Could Forty Seven, Inc.'s (NASDAQ:FTSV) Investor Composition Influence The Stock Price?Could Forty Seven, Inc.'s (NASDAQ:FTSV) Investor Composition Influence The Stock Price?
finance.yahoo.com - March 30 at 12:23 PM
Forty Seven Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business HighlightsForty Seven Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
finance.yahoo.com - March 29 at 12:38 PM
Forty Seven Inc to Host Earnings CallForty Seven Inc to Host Earnings Call
finance.yahoo.com - March 28 at 3:59 PM
Forty Seven Inc. to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 2Forty Seven Inc. to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 2
www.nasdaq.com - March 22 at 12:07 PM
Forty Seven Inc. to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 28, 2019Forty Seven Inc. to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 28, 2019
finance.yahoo.com - March 22 at 12:07 PM
Forty Seven, Inc. Estimate MomentumForty Seven, Inc. Estimate Momentum
www.nasdaq.com - March 18 at 4:02 PM
March Outlook For Forty Seven Inc.March Outlook For Forty Seven Inc.
seekingalpha.com - March 12 at 1:49 PM
Forty Seven Inc. to Present at Oppenheimer 29th Annual Healthcare ConferenceForty Seven Inc. to Present at Oppenheimer 29th Annual Healthcare Conference
finance.yahoo.com - March 12 at 1:49 PM
Forty Seven Inc. to Present at Guggenheim Healthcare Talks Idea Forum | Oncology DayForty Seven Inc. to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day
finance.yahoo.com - February 7 at 11:39 AM
Forty Seven Inc. to Host Key Opinion Leader Breakfast Symposium on FSI-174, anti-cKIT Antibody, on January 22, 2019Forty Seven Inc. to Host Key Opinion Leader Breakfast Symposium on FSI-174, anti-cKIT Antibody, on January 22, 2019
finance.yahoo.com - January 15 at 11:07 AM
Forty Seven Inc. Announces 2019 Strategic Priorities and Expected MilestonesForty Seven Inc. Announces 2019 Strategic Priorities and Expected Milestones
finance.yahoo.com - January 7 at 10:58 AM
Should You Take Comfort From Insider Transactions At Forty Seven, Inc. (NASDAQ:FTSV)?Should You Take Comfort From Insider Transactions At Forty Seven, Inc. (NASDAQ:FTSV)?
finance.yahoo.com - December 21 at 3:28 PM
Forty Seven Inc. Cl AForty Seven Inc. Cl A
www.barrons.com - December 19 at 3:30 PM
Long-Term Outlook For Forty Seven Inc.Long-Term Outlook For Forty Seven Inc.
seekingalpha.com - December 17 at 10:14 AM
Forty Seven Inc. Reports Third Quarter 2018 Financial Results and Recent Business HighlightsForty Seven Inc. Reports Third Quarter 2018 Financial Results and Recent Business Highlights
finance.yahoo.com - November 13 at 8:27 AM
Forty Seven Inc. to Present at the Credit Suisse 27th Annual Healthcare ConferenceForty Seven Inc. to Present at the Credit Suisse 27th Annual Healthcare Conference
finance.yahoo.com - November 7 at 8:37 AM
Forty Seven Inc. to Present New Preclinical Data on 5F9 at the 60th American Society of Hematology (ASH) Annual MeetingForty Seven Inc. to Present New Preclinical Data on 5F9 at the 60th American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 1 at 3:27 PM
Forty Seven Inc. Announces Publication in The New England Journal of Medicine of 5F9 Phase 1b Clinical Data in Non-Hodgkin’s Lymphoma (NHL)Forty Seven Inc. Announces Publication in The New England Journal of Medicine of 5F9 Phase 1b Clinical Data in Non-Hodgkin’s Lymphoma (NHL)
finance.yahoo.com - November 1 at 8:16 AM
Investment Thesis Of Forty SevenInvestment Thesis Of Forty Seven
seekingalpha.com - October 11 at 3:20 PM
Trillium Therapeutics Updates On Lead Lymphoma TrialsTrillium Therapeutics Updates On Lead Lymphoma Trials
seekingalpha.com - October 5 at 7:33 AM
Forty Seven Inc. Appoints Leading Experts in Immuno-Oncology to its Scientific Advisory Board (SAB)Forty Seven Inc. Appoints Leading Experts in Immuno-Oncology to its Scientific Advisory Board (SAB)
finance.yahoo.com - October 3 at 3:19 PM
Forty Seven Inc. Reports Second Quarter 2018 Financial Results and Recent Business HighlightsForty Seven Inc. Reports Second Quarter 2018 Financial Results and Recent Business Highlights
finance.yahoo.com - August 14 at 6:24 AM
Forty Seven Inc. to Present at the 38th Annual Canaccord Genuity Growth ConferenceForty Seven Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference
finance.yahoo.com - August 2 at 3:16 PM
47 Scoop: Trillium Bleeds, Surface Hemorrhages, And Forty Seven Throws In The $47 Million Towel On Synthon Lawsuit47 Scoop: Trillium Bleeds, Surface Hemorrhages, And Forty Seven Throws In The $47 Million Towel On Synthon Lawsuit
seekingalpha.com - August 2 at 5:52 AM
This page was last updated on 7/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel